Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1291 to 1300 of 2733 total matches.

Ferric Citrate (Auryxia) for Hyperphosphatemia

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
Exams Published by The Medical Letter, Inc. • A Nonprofit Organization Table 1. Some Oral Drugs ...
The FDA has approved ferric citrate (Auryxia – Keryx), an oral phosphate binder, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is the second iron-based phosphate binder to be approved in the US, and the first that causes significant systemic absorption of iron. Auryxia is not FDA-approved for treatment of iron deficiency anemia.
Med Lett Drugs Ther. 2015 Dec 7;57(1483):166-7 |  Show IntroductionHide Introduction

Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
to conventional therapy, but its use has been limited by serious GI adverse effects such as ischemic colitis.1 ...
The FDA has approved eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist and delta-opioid receptor antagonist, for oral treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).
Med Lett Drugs Ther. 2016 Jan 4;58(1485):4-5 |  Show IntroductionHide Introduction

In Brief: Pitavastatin Magnesium (Zypitamag) for Hyperlipidemia

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018  (Issue 1549)
significantly more than less intensive regimens. In one meta-analysis, each additional 1 mmol/L (39 mg/dL ...
The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium (Zypitamag – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium (Livalo), which was approved in 2009.1Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death in patients with or at high risk for...
Med Lett Drugs Ther. 2018 Jun 18;60(1549):106 |  Show IntroductionHide Introduction

Osmolex ER - Another Extended-Release Amantadine for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Sep 10, 2018  (Issue 1555)
of levodopa-induced dyskinesia in patients with PD.1 Pronunciation Key Osmolex: oz' mole ex STANDARD ...
The FDA has approved an extended-release tablet formulation of amantadine (Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms (EPS) in adults. An extended-release capsule formulation of amantadine (Gocovri) was approved in 2017 for treatment of levodopa-induced dyskinesia in patients with PD.
Med Lett Drugs Ther. 2018 Sep 10;60(1555):148-50 |  Show IntroductionHide Introduction

Sulfonamide Cross-Reactivity

   
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019  (Issue 1568)
of sulfanilamide. Both antibacterial and nonantibacterial sulfonamide drugs (see Table 1) contain a sulfonamide ...
A reader has questioned why the label for the COX-2 selective NSAID celecoxib (Celebrex, and generics), which contains a sulfonamide moiety, states that it is contraindicated for use in patients with an allergy to sulfonamides, while the labels of some other sulfonamide drugs recommend either caution or no precautions at all. The concept of cross-reactivity among sulfonamide drugs, particularly between antibacterial and nonantibacterial sulfonamides, has been controversial for many years.
Med Lett Drugs Ther. 2019 Mar 25;61(1568):44-6 |  Show IntroductionHide Introduction

Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020  (Issue 1591)
-only oral contraceptives available in the US contain norethindrone (Camila, and others).1 Progestin ...
The FDA has approved a progestin-only oral contraceptive ("minipill") containing drospirenone (Slynd – Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone (Camila, and others). Progestin-only oral contraceptives are similar in efficacy to combination oral contraceptives. They are used predominantly by breastfeeding women and by those in whom estrogen is poorly tolerated or contraindicated. Combination oral contraceptives containing drospirenone and ethinyl estradiol have been available for years.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):18-9 |  Show IntroductionHide Introduction

In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
failure with reduced ejection fraction (HFrEF).1 The indication has now been expanded to include ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga – AstraZeneca) was approved by the FDA in 2020 to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF). The indication has now been expanded to include a reduction in the risk of urgent HF visits and use in adults with any left ventricular ejection fraction (LVEF).
Med Lett Drugs Ther. 2023 Jun 26;65(1679):101-2   doi:10.58347/tml.2023.1679c |  Show IntroductionHide Introduction

Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023  (Issue 1686)
for cardiovascular disease.1 MECHANISM OF ACTION — Inflammation is thought to play an important role ...
Colchicine (Colcrys, and others), which has been available in the US for decades for prophylaxis and treatment of gout flares and other indications in oral formulations that contain 0.6 mg of the drug, has now been approved in 0.5-mg tablets as Lodoco (Agepha) to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple risk factors for cardiovascular disease.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):156-7   doi:10.58347/tml.2023.1686b |  Show IntroductionHide Introduction

Pioglitazone (Actos)

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 1999  (Issue 1066)
dosage Cost 1 Troglitazone − Rezulin (Parke-Davis) 200 to 600 mg once 2 89.28 Rosiglitazone ...
Pioglitazone is the third thiazolidinedione ("glitazone") to be marketed in the USA for treatment of type 2 diabetes. Thiazolidinediones decrease resistance to insulin.
Med Lett Drugs Ther. 1999 Nov 19;41(1066):112 |  Show IntroductionHide Introduction

In Brief: Cardiovascular Safety of Varenicline (Chantix)

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2011  (Issue 1371)
and suicidal ideation, appears to be the most effective drug available for treatment of tobacco dependence.1 ...
Varenicline (Chantix), which has been associated with neuropsychiatric symptoms such as agitation, depressed mood, changes in behavior and suicidal ideation, appears to be the most effective drug available for treatment of tobacco dependence.1 Recently, the FDA warned that varenicline may also increase the risk of cardiovascular adverse events in patients with cardiovascular disease.2 This warning was based on the results of a 12-week randomized trial in 714 smokers with stable cardiovascular disease. The drug was effective in helping patients stop smoking; long-term quit rates (at 52 weeks)...
Med Lett Drugs Ther. 2011 Aug 22;53(1371):65 |  Show IntroductionHide Introduction